Investigational Drug Service Selected Publications

  • Adjei AA, Dy GK, et al. A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors. J Clin Oncol 2016; 34(15)_suppl (May 2016) 2560-2560.
  • Chen H, Dy G, et al. A Phase II Study of Etirinotecan Pegol (NKTR-102), a Topoisomerase-I lnhibitor Polymer Conjugate, in Small Cell Lung Cancer; Journal of Thoracic Oncology; 12(1), Supplement, S695–S696
  • Dy G, Kim ES, et al. A phase II randomized, placebo-controlled trial evaluating nintedanib versus placebo as prophylaxis against radiation pneumonitis in patients with unresectable non-small cell lung cancer (NSCLC ) undergoing chemoradiation therapy (CRT): A National Comprehensive Cancer Network-sponsored study. J Clin Oncol 2016 34(15)_suppl
  • Adjei A, Dy, G, et al. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors, Invest New Drugs 2017 35(1); 47-58
  • Rosen L, Ma W, Adjei A, et al. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs; 2016 34(5); 604-613
  • Boland P, Iyer R, Ma W, et al. A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer J Clin Oncol 2017; 35(4) suppl.759
  • Puzanov I, Dy G, Adjei A, et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors Invest New Drugs 2015 33; 159-168
  • Ngamphaiboon N, Dy G, et al. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors Invest New Drugs 2015 33; 225-232
  • Bakhribah H, Dy G, Adjei AA, et al. A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod in patients (pts) with advanced cancers. J Clin Oncol 33, no. 15_suppl (May 2015) 3063-3063 abstract
  • Fetterly G, Dy G, Ma W, et al. A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors. J Clin Oncol 32, no. 15_suppl (May 2014) 2603-2603 abstract
  • Naing A, Dy G, et al. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs 2013; 31: 967-973
  • Ma, W, Dy G, Adjei AA, et al. A phase I and pharmacokinetic study of a weekly dosing schedule of paclitaxel injection concentrate for nano-dispersion (PICN) in patients with advanced solid tumors. J Clin Oncol 32, no. 15_suppl (May 2014) 2566-2566 abstract
  • Ma, W, Dy G, Adjei AA, et al. A pharmacokinetic and dose-escalating study of paclitaxel injection concentrate for nano-dispersion (PICN) alone and with carboplatin in patients with advanced solid tumors. J Clin Oncol 31, no. 15_suppl (May 2013) 2557-2557 abstract